Submission Details

Design Rationale:

Note these are not covalent In support of the clinical trials AI and quantum chemistry and systems biology of virus-host interactions The top 4 in various combination will be going through trial soon chloroquins:submitted as this where I can take the best part from norway hydroxychloroquine/Hydroxychloroquine Sulfate Hydroxychloroquine mono and di-phosphate Losartan which can draw from the SARS 1 experience and MERS already for ML and AI and the records in Hng KonG and mainland for nCOV-SARS 1 These belwo will come later we only have preliminary dockings here remdesivir lopinavir/ritonavir Montelukast CL3 is the one I submitted with the pdb with docking nCOV-SARS 1 ( side effects have been reported ) Ribavirin Preventive We also have looked at some natural compounds with whuan lately (OC1C=C([C@@H]2CC(=O)C3C(=CC(=CC=3O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O4)O3)O2)C=CC=1OC O=C1C2C(=C(C(=CC=2O)O)O)OC(C2C=CC(O)=CC=2)=C1O * O=C1C2C(=C(C(=CC=2O)O)O)OC(C2C=CC(O)=CC=2)=C1O COC1C(O)=CC(C2OC3C=C(O)C=C(C=3C(=O)C2)O)=CC=1 * COC1C(O)=CC(C2OC3C=C(O)C=C(C=3C(=O)C2)O)=CC=1 that makes sense based on an evodevoeco approach to the coronas in a combinatorial and comparative framwework morover they coevolved and can be produced fast with GMP and isolated in relatively large amounts and high purity from staple crops and from biorests they do dock quite well with 6lu7 (CASP) and makes sense in a evodevo context of the coronaviruses ( broad spectrum) is now in a clinical double blind crossover study the factory set up is ready in at lest three countries once the initial study( last crossover was interfered by the outbreak in Spain but last crossover nacebo /placebo group we will also with an will also be offerd IgM and IgG kits) but the same line of reasoning goes here a prepared nes for that this is evolution in real time as well as a need to know a bit more if some of these especially natural compound can scale well it also can be done more efficient and serve as substrates for new compounds and synbio pathway redesigns/scaffolds We also have some peptides with O and N glyosylation /moieties and modification which might serve as boosting based on stable epitopes of the M in nCOV but are not sure if that is on your agenda ? The@®© MIRRIMAX >SGI_translation-2019-06-21T16:59:53.818Z GCTCATTGCAGTCTGCGTGCTCATGCT NOSARSCOVID also take there will be clinical trials on acute intervention using nitric oxide (but that is more a respiratory acute intervention that is dependent up on Nitric Oxide Gas Inhalation Therapy for Mechanically Ventilated Patients With Severe Acute Respiratory Syndrome Caused by SARS-CoV2: a Randomized Clinical Trial. but t that will have to be dependent upon indirect mesures of inducible NOS

Other Notes:

Not necessarily for production at this time however as more host -virion interactions become available and the randomized clinical trial progresses it would be of interest to learn more about possible systemsbiology and systemic effects of the drugs effects and in producing antibodies for immonogold will rely on that the biological active molecules is available in high purity as a control mechanism for in situ detection of the molecules (in biopsies ) and high resolution microscopic and spectroscopic tehniques ( forensics) and redesign and of course rationale on scaling up in due time once we have the data in from the studies with regards to testing and experiements which in vitro and cell lines do you have in place from especially the respiratory system and tracts ? PS there may be biopsies and cells available for Immunogold etc but currently grade 3.3.

Inspired By:

Download PDB File